Pipeline-focused public companies
Find biotechnology and pharmaceutical companies by market profile and drug-development maturity, then open each ticker for its stock, pipeline and catalyst research page.
| Company | Price | Market cap | Pipeline | Next catalyst | Open |
|---|---|---|---|---|---|
| SA SAGESage Therapeutics | $8.68+0.0% | $544.9M | 5 assetsStage unavailable | No dated catalyst | |
| SA SANASana Biotechnology | $3.91+4.5% | $1.17B | 8 assetsPhase 1 | UP421Phase 1 · Data readout | |
The screener is the parent research index for individual ticker pages such as CAPR. Filter the biotech company universe here, then open a company to review its stock snapshot, drug assets, clinical stage and dated catalysts. Quote information is a cached market snapshot and may be delayed.
| $2.38+0.0% |
| $115.0M |
2 assetsStage unavailable |
| No dated catalyst |
| SC SCLXScilex Holding Company | $5.73-1.2% | $40.3M | 1 assetsStage unavailable | No dated catalyst |
| SC SCPXScorpius Holdings | $0.00+0.0% | $61,142 | 4 assetsStage unavailable | No dated catalyst |
| SC SCYXSCYNEXIS | $5.10-2.3% | $50.7M | 5 assetsPhase 1 | SCY-247Phase 1 · Data readout |
| SD SDGRSchrodinger Inc | $19.71+0.7% | $1.47B | 5 assetsPhase 1 | No dated catalyst |
| SE SEPNSepterna | $40.00-1.9% | $1.87B | 2 assetsPhase 1 | SEP-479 (PTH1R Agonist)Phase 1 · Data readout |
| SG SGMOSangamo Therapeutics | $0.07+0.0% | $30.7M | 8 assetsStage unavailable | No dated catalyst |
| SG SGMTSagimet Biosciences | $10.25+0.7% | $637.1M | 8 assetsStage unavailable | No dated catalyst |
| SG SGPSpyGlass Pharma | $26.51+1.1% | $886.7M | 2 assetsStage unavailable | No dated catalyst |
| SG SGTXSigilon Therapeutics | $22.47+0.0% | — | 2 assetsStage unavailable | No dated catalyst |
| SI SIGASIGA Technologies | $3.04+2.4% | $218.4M | 2 assetsStage unavailable | No dated catalyst |
| SI SIONSionna Therapeutics | $5.29-4.2% | $238.8M | 2 assetsPhase 1 | No dated catalyst |
| SK SKYESkye Bioscience | $0.28-0.3% | $1.2M | 2 assetsPhase 2a | NimacimabPhase 2a · Data readout |
| SL SLDBSolid Biosciences | $9.30+2.2% | $997.2M | 4 assetsPhase 1b | SGT-212 (dual route)Phase 1b · Data readout |
| SL SLGLSol-Gel | $77.73-1.0% | $254.1M | 6 assetsPhase 3 | SGT-610 (Patidegib)Phase 3 · Data readout |
| SL SLNSilence Therapeutics | $13.27+0.8% | $824.8M | 3 assetsStage unavailable | No dated catalyst |
| SL SLNOSoleno Therapeutics | $53.01+0.0% | $2.76B | 1 assetsStage unavailable | No dated catalyst |
| SL SLRNAcelyrin Inc. | $2.27+0.0% | $229.2M | 6 assetsStage unavailable | No dated catalyst |
| SL SLSSELLAS Life Sciences Group | $15.46+15.4% | $3.12B | 8 assetsPhase 3 | SLS009 (GFH009) +/- venetoclax & azacitidinePhase 2 · Data readout |
| SM SMMTSummit Therapeutics | $13.16+5.9% | $10.50B | 14 assetsPDUFA | Ivonescimab + chemotherapyPDUFA · Approval decision |
| SN SNDXSyndax Pharmaceuticals | $19.65-0.5% | $1.75B | 22 assetsPhase 3 | Revumenib w/ 7+3 cytarabine + daunorubicinPhase 1 · Data readout |
| SN SNPXSynaptogenix | $24.55+1.2% | — | 2 assetsStage unavailable | No dated catalyst |
| SN SNSESensei Biotherapeutics | $13.85+0.0% | $18.6M | 5 assetsPhase 2 | Piktor (PI3K/mTOR Inhibitor)Phase 2 · Data readout |
| SN SNTISenti Biosciences | $0.39-10.9% | $12.1M | 2 assetsStage unavailable | No dated catalyst |
| SN SNYSanofi | $45.85+1.6% | $109.86B | 17 assetsStage unavailable | No dated catalyst |
| SO SONNSonnet BioTherapeutics | $1.26-59.4% | $8.6M | 4 assetsStage unavailable | No dated catalyst |
| SP SPPISpectrum Pharmaceuticals | $1.03+0.0% | — | 2 assetsStage unavailable | No dated catalyst |
| SP SPRBSpruce Biosciences | $51.58-0.8% | $148.2M | 5 assetsStage unavailable | No dated catalyst |
| SP SPRCSciSparc Ltd | $6.70-0.7% | $3.8M | 2 assetsStage unavailable | No dated catalyst |
| SP SPRO Spero Therapeutics | $1.22+0.8% | $71.0M | 4 assetsStage unavailable | No dated catalyst |
| SP SPRYARS Pharmaceuticals | $5.51+0.0% | $547.5M | 3 assetsPhase 2b | neffy® (epinephrine nasal spray)Phase 2b · Data readout |
| SP SPTXSeaport Therapeutics | $24.31+1.1% | $1.30B | 4 assetsPhase 2b | GlyphAllo/Glyph Allopregnanolone (SPT-300) (Neuroactive Steroid)Phase 1 · Data readout |
| SQ SQZBSQZ Biotechnologies Company | $0.02+0.0% | $707,787 | 3 assetsStage unavailable | No dated catalyst |
| SR SRNESorrento Therapeutics | $0.00+0.0% | $441,024 | 12 assetsStage unavailable | No dated catalyst |
| SR SRPTSarepta Therapeutics | $18.79-2.2% | $1.98B | 14 assetsPhase 1/2 | SRP-1003Phase 1/2 · Data readout |
| SR SRRKScholar Rock Holding Corp | $56.50+2.3% | $6.88B | 6 assetsPDUFA | Apitegromab (SRK-015) PDUFA · Approval decision |
| ST STOKStoke Therapeutics | $32.29+2.8% | $2.08B | 2 assetsPhase 1 | STK-002Phase 1 · Data readout |
| ST STROSutro Biopharma | $21.04-0.6% | $348.9M | 9 assetsPhase 1 | STRO-004Phase 1 · Data readout |